LSV Asset Management Has $591,000 Stake in Prestige Consumer Healthcare Inc. $PBH

LSV Asset Management reduced its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 32.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,400 shares of the company’s stock after selling 3,500 shares during the quarter. LSV Asset Management’s holdings in Prestige Consumer Healthcare were worth $591,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in shares of Prestige Consumer Healthcare by 45.3% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock worth $135,903,000 after acquiring an additional 493,199 shares during the period. Geode Capital Management LLC raised its position in Prestige Consumer Healthcare by 0.7% in the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock worth $112,843,000 after purchasing an additional 9,455 shares in the last quarter. Invesco Ltd. lifted its stake in Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock worth $113,635,000 after purchasing an additional 261,537 shares during the period. Congress Asset Management Co. boosted its holdings in Prestige Consumer Healthcare by 1.8% during the second quarter. Congress Asset Management Co. now owns 1,009,595 shares of the company’s stock valued at $80,616,000 after purchasing an additional 18,015 shares in the last quarter. Finally, Westwood Holdings Group Inc. boosted its holdings in Prestige Consumer Healthcare by 2.4% during the second quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company’s stock valued at $70,420,000 after purchasing an additional 20,626 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Oppenheimer dropped their target price on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, October 21st. Finally, Jefferies Financial Group cut their price target on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a report on Monday, October 27th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $85.33.

Prestige Consumer Healthcare Stock Up 0.4%

Shares of NYSE:PBH opened at $59.43 on Friday. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. The firm has a market cap of $2.86 billion, a P/E ratio of 13.95, a P/E/G ratio of 1.93 and a beta of 0.41. Prestige Consumer Healthcare Inc. has a 12 month low of $58.03 and a 12 month high of $90.04. The company’s 50-day moving average price is $61.74 and its two-hundred day moving average price is $71.73.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. During the same period in the prior year, the business earned $1.09 earnings per share. Prestige Consumer Healthcare’s quarterly revenue was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. As a group, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.